Deputy Director of the Clinical Research Division, Psychiatry & Human Behavior
School of Medicine

1. Potkin SG, Basile VS, Jin Y, Masellis M, Badri F, Keator D, Wu JC, Alva G, Carreon DT, Bunney WE Jr, Fallon JH, Kennedy JL. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry. 2003 Jan;8(1):109-13
2. Alva G, Potkin SG. Alzheimer disease and other dementias. Clin Geriatr Med 19(2003)76—776
3. Alva G. The challenge of dementia: Preserving cognition and behavior. Cognitive and Behavioral Aspect of Neuropsychiatric Disorders, 2002
4. Potkin SG, Thyrum PT, Bera R, Carreon D, Alva G, Kalali AH, Yeh C. Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Clin Ther. 2002 Nov;24(11):1809-23
5. Potkin SG, Alva G, Keator D, Carreon D, Fleming K, Fallon JH. Brain metabolic effects of Neotrofin in patients with Alzheimer's disease. Brain Res. 2002 Sep 27;951(1):87-95
6. Potkin SG, Thyrum PT, Alva G, Carreon D, Yeh C, Kalali A, Arvanitis LA; Pharmacokinetic Study Group. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol. 2002 Apr;22(2):174-82
7. Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol. 2002 Apr;22(2):121-30.
8. Potkin SG, Alva G, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu JC, Fallon JH. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am J Psychiatry. 2002 Feb;159(2):227-37
9. Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol. 2001 Sep;4(3):223-30.
10. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, Potkin SG, Alva G, Kalow W, Macciardi FM, Kennedy JL. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry. 2000 Jul;5(4):410-7.

Noradrenergic Assessment of Memory Capacity A fixed-dose, open-label, single-center, investigator initiated pilot study of the safety and efficacy of Venlafaxine as adjunct therapy to cholinesterase inhibitors on the improvement of cognitive function in non-depressed patients with Alzheimer’s dementia Role: Principal Investigator Alva) Novartis A Prospective, 26-week, single-arm, open-label, multi-center, pilot study evaluating the efficacy and safety of exelon 3 to 12 mgs/day in patients with mixed dementia Role: Principal Investigator Corcept A double-blind, placebo-controlled trial of the safety and efficacy of C-1073 (Mifepristone) as adjunctive therapy in alzheimer’s disease. Role: Principal Investigator (Alva) 11/01/00-10/31/01 COMPLETED Warner Lambert A Placebo Controlled Study of Pregabalin and Paroxetine in Patients with Panic Disorder The major goals of this project were to test the safety and efficacy of a novel antiepileptic drug in panic disorder Role: Principal Investigator (Alva) 10/27/00-10/26/01 COMPLETED Warner Lambert A Placebo Controlled Study of Pregabalin in Elderly Patients with Generalized Anxiety Disorder The major goals of this project were to see if a novel antiepileptic agent would have anti anxiety effects in an elderly patient cohort Role: Principal Investigator Protocol C-1073-02 (Alva) 11/01/01-10/31/02 COMPLETED Corcept A Phase III, Randomized, Double-Blind, Placebo-Controlled, Study of Safety and Efficacy of C-1073 (Mifepristone) in Patients with Major Depressive Disorder with Psychotic Features The major goal of this project was to test if a glucocorticoid receptor blocking drug along would offset psychotic depression Role: Principal Investigator Protocol C-1073-03 (Alva) 11/01/01-10/31/02 COMPLETED Corcept A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of C-1073 (Mifepristone) in Patients with Major Depressive Disorder with Psychotic Features Who Are Not Receiving Antidepressants or Antipsychotics The major goals of this project were to test a glucocorticoid receptor blocking drug and the immediate and longer term effects of psychotic depression Role: Principal Investigator Protocol C-1073-04 (Alva) 11/01/01-10/31/02 COMPLETED Corcept Efficacy of C-1073 (Mifepristone) in Patients With Major Depressive Disorder With Psychotic Features Who Have Previously Demonstrated a Rapid Response to Either C-1073-02 or C-1073-03 The major goals of this project were test if those individuals previously responding to a glucocorticoid blocking drug in offsetting their psychotic depression would continue to show clinical benefit Role: Principal Investigator

1998-present Council, California Psychiatric Association

2002-present President of the Orange County Psychiatric Soci

Link to this profile
https://faculty.uci.edu/profile/?facultyId=5043

Last updated
01/21/2004